169 related articles for article (PubMed ID: 12935811)
1. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies.
Johnston A; Uren E; Johnstone D; Wu J
Biologicals; 2003 Sep; 31(3):213-21. PubMed ID: 12935811
[TBL] [Abstract][Full Text] [Related]
2. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of lipid enveloped viruses by octanoic Acid treatment of immunoglobulin solution.
Dichtelmüller H; Rudnick D; Kloft M
Biologicals; 2002 Jun; 30(2):135-42. PubMed ID: 12127315
[TBL] [Abstract][Full Text] [Related]
4. Partitioning and inactivation of viruses by the caprylic acid precipitation followed by a terminal pasteurization in the manufacturing process of horse immunoglobulins.
Mpandi M; Schmutz P; Legrand E; Duc R; Geinoz J; Henzelin-Nkubana C; Giorgia S; Clerc O; Genoud D; Weber T
Biologicals; 2007 Oct; 35(4):335-41. PubMed ID: 17470396
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of lipid-enveloped viruses in proteins by caprylate.
Lundblad JL; Seng RL
Vox Sang; 1991; 60(2):75-81. PubMed ID: 2031341
[TBL] [Abstract][Full Text] [Related]
6. Assessment of viral inactivation during pH 3.3 pepsin digestion and caprylic acid treatment of antivenoms.
Burnouf T; Terpstra F; Habib G; Seddik S
Biologicals; 2007 Oct; 35(4):329-34. PubMed ID: 17363271
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products.
Remington KM; Trejo SR; Buczynski G; Li H; Osheroff WP; Brown JP; Renfrow H; Reynolds R; Pifat DY
Vox Sang; 2004 Jul; 87(1):10-8. PubMed ID: 15260817
[TBL] [Abstract][Full Text] [Related]
8. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.
Bos OJ; Sunyé DG; Nieuweboer CE; van Engelenburg FA; Schuitemaker H; Over J
Biologicals; 1998 Dec; 26(4):267-76. PubMed ID: 10403030
[TBL] [Abstract][Full Text] [Related]
9. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography.
Lebing W; Remington KM; Schreiner C; Paul HI
Vox Sang; 2003 Apr; 84(3):193-201. PubMed ID: 12670368
[TBL] [Abstract][Full Text] [Related]
10. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
11. Manufacturing process of anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance.
Morrica A; Nardini C; Falbo A; Bailey AC; Bucci E
Biologicals; 2003 Sep; 31(3):165-73. PubMed ID: 12935804
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion.
Torgeman A; Mador N; Dorozko M; Lifshitz A; Eschar N; White MD; Wolf DG; Epstein E
Biologicals; 2017 Jul; 48():24-27. PubMed ID: 28633975
[TBL] [Abstract][Full Text] [Related]
13. Viral safety of APOSECTM: a novel peripheral blood mononuclear cell derived-biological for regenerative medicine.
Gugerell A; Sorgenfrey D; Laggner M; Raimann J; Peterbauer A; Bormann D; Suessner S; Gabriel C; Moser B; Ostler T; Mildner M; Ankersmit HJ
Blood Transfus; 2020 Jan; 18(1):30-39. PubMed ID: 30865581
[TBL] [Abstract][Full Text] [Related]
14. Chikungunya virus and the safety of plasma products.
Leydold SM; Farcet MR; Kindermann J; Modrof J; Pölsler G; Berting A; Howard MK; Barrett PN; Kreil TR
Transfusion; 2012 Oct; 52(10):2122-30. PubMed ID: 22339168
[TBL] [Abstract][Full Text] [Related]
15. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
Borovec S; Broumis C; Adcock W; Fang R; Uren E
Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
[TBL] [Abstract][Full Text] [Related]
16. [Inactivation of BVDV (experimental model for hepatitis C) using low pH and heat treatment in intravenous human immunoglobulins].
Ruibal Brunet IJ; Noa Romero E; Rivero Mas AT; Martín García RZ
Sangre (Barc); 1999 Oct; 44(5):352-6. PubMed ID: 10618912
[TBL] [Abstract][Full Text] [Related]
17. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
18. Virus inactivation by protein denaturants used in affinity chromatography.
Roberts PL; Lloyd D
Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
[TBL] [Abstract][Full Text] [Related]
19. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
20. Iodine-mediated inactivation of lipid- and nonlipid-enveloped viruses in human antithrombin III concentrate.
Highsmith F; Xue H; Chen X; Benade L; Owens J; Shanbrom E; Drohan W
Blood; 1995 Jul; 86(2):791-6. PubMed ID: 7606009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
